Literature DB >> 6124472

Direct effect of glibenclamide on guanylate cyclase activity in the rat in vitro.

D L Vesely.   

Abstract

Glibenclamide enhanced the activity in the rat of guanylate cyclase in a number of extra-pancreatic tissues. Thus, glibenclamide enhanced guanylate cyclase activity in vitro two- to threefold in liver, kidney, heart, spleen and colon at a concentration of 1 mumol/l. Dose-response curves of glibenclamide on hepatic guanylate cyclase revealed that more than half-maximal stimulation was observed at a concentration as low as 10 nmol/l (p less than 0.001) and no stimulation of guanylate cyclase was seen when the concentration was decreased to 1 nmol/l. Maximal enhancement was seen at 100 nmol/l of glibenclamide. Varying the concentration of the guanylate cyclase co-factor manganese had no effect on the glibenclamide enhancement of guanylate cyclase. In addition to the increased insulin receptors found recently in monocytes and fibroblasts, the present findings may help explain the extra-pancreatic effects of glibenclamide and possibly of other sulphonylurea drugs.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6124472     DOI: 10.1007/bf00281304

Source DB:  PubMed          Journal:  Diabetologia        ISSN: 0012-186X            Impact factor:   10.122


  15 in total

1.  Activation of guanylate cyclase by superoxide dismutase and hydroxyl radical: a physiological regulator of guanosine 3',5'-monophosphate formation.

Authors:  C K Mittal; F Murad
Journal:  Proc Natl Acad Sci U S A       Date:  1977-10       Impact factor: 11.205

2.  Chlorpropamide and tolbutamide inhibition of adenosine 3'5' cyclic monophosphate phosphodiesterase.

Authors:  G Brooker; M Fichman
Journal:  Biochem Biophys Res Commun       Date:  1971-03-05       Impact factor: 3.575

3.  Role of adenosine 3',5'-monophosphate in the effects of insulin and anti-insulin serum on liver metabolism.

Authors:  L S Jefferson; J H Exton; R W Butcher; E W Sutherland; C R Park
Journal:  J Biol Chem       Date:  1968-03-10       Impact factor: 5.157

4.  The metabolism of the pancreatic beta-cells of mice in the presence of hypoglycaemic sulphonylureas.

Authors:  S Westman; C Hellerström
Journal:  Postgrad Med J       Date:  1970-12       Impact factor: 2.401

5.  Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.

Authors:  G Sartor; A Melander; B Scherstén; E Wåhlin-Boll
Journal:  Diabetologia       Date:  1980-01       Impact factor: 10.122

6.  Decreased rat hepatic guanylate cyclase activity in streptozotocin-induced diabetes mellitus.

Authors:  D L Vesely; A Castro; G S Levey
Journal:  Diabetes       Date:  1977-04       Impact factor: 9.461

7.  Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide.

Authors:  H Beck-Nielsen; O Pedersen; H O Lindskov
Journal:  Acta Endocrinol (Copenh)       Date:  1979-03

8.  Effect of glucose/sulfonylurea interaction on release of insulin, glucagon, and somatostatin from isolated perfused rat pancreas.

Authors:  S Efendić; F Enzmann; A Nylén; K Uvnäs-Wallensten; R Luft
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

9.  The effect of sulfonylurea drugs on rabbit myocardial contractility, canine purkinje fiber automaticity, and adenyl cyclase activity from rabbit and human hearts.

Authors:  K C Lasseter; G S Levey; R F Palmer; J S McCarthy
Journal:  J Clin Invest       Date:  1972-09       Impact factor: 14.808

10.  Testosterone and its precursors and metabolites enhance guanylate cyclase activity.

Authors:  D L Vesely
Journal:  Proc Natl Acad Sci U S A       Date:  1979-07       Impact factor: 11.205

View more
  1 in total

1.  Trial of sulfonylurea in combination with insulin in the therapy of diabetes type I and II. Evidence against a primary extrapancreatic receptor effect.

Authors:  W P Bieger; R Dlugosch; A Rettenmeier; H D Holler; H Bert; W Schwarz; W Fiehn; J Merkt; H Weicker
Journal:  Klin Wochenschr       Date:  1984-07-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.